Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$53.76 USD
+0.86 (1.63%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$53.76 USD
+0.86 (1.63%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug
by Arpita Dutt
It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.
Celldex Ends Phase II Enrollment for Breast Cancer Candidate
by Zacks Equity Research
Celldex (CLDX) announces completion of enrollment in METRIC, a phase IIb study, evaluating glembatumumab vedotin for breast cancer treatment.
Here's Why Clovis Stock Is Up Almost 60% So Far in 2017
by Zacks Equity Research
Clovis Oncology (CLVS) stock is on the rise. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.
Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada
by Zacks Equity Research
Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.
Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo
by Arpita Dutt
Key highlights this week in the pharmaceutical sector include the launch of a drug pricing probe, a resignation from the President's manufacturing council and data on Bristol-Myers' (BMY) Opdivo.
Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx
by Zacks Equity Research
Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.
FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa
by Zacks Equity Research
FDA acknowledges Portola's (PTLA) resubmitted BLA for AndexXa to raise hopes for an urgent need of antidotes for Factor Xa inhibitors in the market.
Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced disappointing top-line results from the CheckMate-214 trial on Opdivo in renal cell carcinoma.
Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses
by Zacks Equity Research
Clovis Oncology (CLVS) reported significant increase in Rubraca sales in the second quarter. Moreover, the company is focused on expanding Rubraca's label in second-line ovarian cancer.
Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review
by Zacks Equity Research
Gilead Sciences, Inc.'s(GILD) NDA for an investigational, fixed-dose combination of bictegravir for the treatment of HIV-1 infection obtained priority review.
Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag
by Zacks Equity Research
Nektar (NKTR) reports wider-than-expected loss with revenues falling shy of estimates. However, the top line rises year over year, courtesy an increase in product sales and royalty revenues.
Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure
by Arpita Dutt
This week, focus was on earnings announcements from companies like Mylan (MYL), Perrigo and Endo.
AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.
Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q2 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.
Horizon Pharma (HZNP) Q2 Earnings & Sales Top, Raises View
by Zacks Equity Research
Horizon Pharma plc (HZNP) topped both earnings and sales estimate in second-quarter 2017 and raised its sales guidance for 2017.
Q2 Earnings Fail to Impress Pharma ETF
by Sweta Killa
The string of earnings beat failed to boost pharma ETFs.
Infinity (INFI) Q2 Loss Wider than Expected, View Intact
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) reported a wider-than-expected loss in second-quarter 2017 due to the termination of an agreement with AbbVie.
Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals
by Arpita Dutt
Pfizer's (PFE) results were mixed while Teva had a dismal quarter with the company missing estimates as well as cutting its outlook and guidance.
Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales
by Zacks Equity Research
Exelixis' (EXEL) second-quarter results were impressive where in both earnings and sales beat estimates driven by strong uptake of Cabometyx.
Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top
by Zacks Equity Research
Aduro (ADRO) incurs loss in Q2 but revenues beat estimates. However, the same declines year over year, courtesy a milestone payment from the year-ago quarter.
Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses
by Zacks Equity Research
Clovis Oncology (CLVS) reported narrower year-over-year loss in the second quarter on the back of impressive Rubraca sales. The company is also actively working on Rubraca's label expansion.
The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts
Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong
by Zacks Equity Research
Incyte (INCY) reported a wider-than-expected loss in the second quarter but revenues beat expectations.
What's in the Cards for Celldex (CLDX) this Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics's (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.
Key FDA Events to Watch Out for in Aug 2017
by Arpita Dutt
Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax's (DVAX) hepatitis B vaccine?